MDR pathogenic bacteria are an emerging threat to human life globally. Engineered phage therapy could play an important future role treating highly resistant pathogens, due to the orthogonal route of attack by phage compared with traditional small molecule therapies. High-throughput phage engineering facilitated by biofoundries is needed to create repositories of clinical-grade phage to treat the most serious AMR cases across the globe.
Contract developer and manufacturer Patheon has agreed to pay $255 million to buy Belgian firm Vion’s Banner Pharmacaps, a specialty pharma business focused on the geltain-based dosage forms.
Team develops method to make therapeutic proteins more stable
Researchers at the Massachusetts General Hospital have developed a fluorescent mouse model of the most common form of muscular dystrophy, myotonic dystrophy type 1, which could help scientists find new treatments for the genetic disorder.
Lead candidate is expected to begin Phase II trials this year in Gram-negative infections.
Companies to collaborate on trials for Eisai's Lenvima®, alone and in combination with Merck's Keytruda®, in additional oncology indications
BioNTech said today it agreed to acquire the operational antibody generation unit of MAB Discovery for an undisclosed price, in a deal that builds...
Company restated proposals in hopes that the agency’s commissioner will reverse ODAC’s decision.
NewLink wins FDA nod for Phase I trials as J&J and Bavarian Nordic plan first human studies for combo regimen in 2015